Clinical Trial

Study of GS-3242 in Participants With HIV-1; Substudy-05

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-05 is to learn more about the study drug GS-3242 in PWH.
Protocol Amendment History 3 changes
critical Trial completed 2026-05-12
notable Enrollment reduced: 30 -> 27 participants 2026-05-12
minor Completion moved earlier: 2027-02 -> 2026-04-16 2026-05-12
Trial Details
NCT Number NCT07001319
Lead Sponsor Gilead Sciences
Conditions HIV-1-infection
Enrollment 27 participants
Start Date 2025-05-29
Primary Completion 2026-03-03 (estimated)
Study Completion 2026-04-16 (estimated)
Updated on ClinicalTrials.gov 2026-05-11